NewcelX Ltd. (NCEL)Healthcare | Biotechnology | Kloten, Switzerland | NasdaqCM
3.19 USD
-0.23
(-6.725%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.33 +0.14 (4.389%) ⇧ (Aug. 28, 2026, 4:04 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:27 a.m. EDT
The investment case for this biotechnology firm is currently overwhelmed by severe structural deterioration. While insiders hold a significant stake, suggesting alignment of interest, the company is bleeding value rapidly with negative free cash flow and a deteriorating balance sheet where debt significantly outweighs equity. The market has already priced in this distress, evidenced by a catastrophic multi-year decline where the stock has lost over 97% of its value, including two consecutive years of double-digit percentage drops recently. Although there is a massive gap between the current price and the consensus analyst target, such valuations in distressed biotech often reflect a 'value trap' rather than a bargain, given the lack of profitability and the high risk of further dilution or insolvency. With no dividend to provide income and a business model that requires substantial capital expenditure without current revenue generation, the outlook remains deeply bearish. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.068583 |
| AutoARIMA | 0.069230 |
| AutoETS | 0.069392 |
| MSTL | 0.069553 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 0.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.269 |
| Excess Kurtosis | -0.82 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 4.897 |
| Market Cap | 18,425,848 |
| Forward P/E | -5.32 |
| Previous Name | Kadimastem Ltd |
| Website | https://newcelx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.83398056 |
| Address1 | Hohstrasse 1 |
| All Time High | 2,940.0 |
| All Time Low | 1.83 |
| Ask | 3.94 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 14,640 |
| Average Daily Volume3 Month | 20,953 |
| Average Volume | 20,953 |
| Average Volume10Days | 14,640 |
| Bid | 3.0 |
| Bid Size | 7 |
| Book Value | 1.51 |
| City | Kloten |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Switzerland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.19 |
| Current Ratio | 0.759 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.3701 |
| Day Low | 3.19 |
| Debt To Equity | 4.897 |
| Display Name | NewcelX |
| Ebitda | -2,507,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -6.067 |
| Enterprise Value | 15,209,137 |
| Eps Current Year | -1.18 |
| Eps Forward | -0.6 |
| Eps Trailing Twelve Months | -2.16 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 41 44 512 21 51 |
| Fifty Day Average | 3.60398 |
| Fifty Day Average Change | -0.41398 |
| Fifty Day Average Change Percent | -0.11486745 |
| Fifty Two Week Change Percent | -83.398056 |
| Fifty Two Week High | 24.6 |
| Fifty Two Week High Change | -21.41 |
| Fifty Two Week High Change Percent | -0.8703252 |
| Fifty Two Week Low | 1.83 |
| Fifty Two Week Low Change | 1.36 |
| Fifty Two Week Low Change Percent | 0.74316937 |
| Fifty Two Week Range | 1.83 - 24.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,611,930,600,000 |
| Float Shares | 2,483,586 |
| Forward Eps | -0.6 |
| Forward P E | -5.3166666 |
| Free Cashflow | -2,728,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Fullday Change | -0.23 |
| Fullday Change Percent | -6.72515 |
| Fullday Price | 3.33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.68059 |
| Held Percent Institutions | 0.013459999 |
| Implied Shares Outstanding | 5,776,128 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,761,868,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland. |
| Long Name | NewcelX Ltd. |
| Market | us_market |
| Market Cap | 18,425,848 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_224505747 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-08-28 |
| Net Income To Common | -8,300,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 19,754,357 |
| Number Of Analyst Opinions | 1 |
| Open | 3.37 |
| Operating Cashflow | -2,766,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 41 44 512 21 50 |
| Post Market Change | 0.13999987 |
| Post Market Change Percent | 4.3887105 |
| Post Market Price | 3.33 |
| Post Market Time | 1,787,947,446 |
| Prev Name | Kadimastem Ltd |
| Previous Close | 3.42 |
| Price Eps Current Year | -2.70339 |
| Price Hint | 4 |
| Price To Book | 2.112583 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.579 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.23000002 |
| Regular Market Change Percent | -6.725147 |
| Regular Market Day High | 3.3701 |
| Regular Market Day Low | 3.19 |
| Regular Market Day Range | 3.19 - 3.3701 |
| Regular Market Open | 3.37 |
| Regular Market Previous Close | 3.42 |
| Regular Market Price | 3.19 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 12,477 |
| Return On Assets | -0.25935 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 5,776,128 |
| Shares Percent Shares Out | 0.0064 |
| Shares Short | 36,949 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 56,509 |
| Short Name | NewcelX Ltd. |
| Short Percent Of Float | 0.0112 |
| Short Ratio | 2.68 |
| Source Interval | 15 |
| Symbol | NCEL |
| Target High Price | 23.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 23.0 |
| Target Median Price | 23.0 |
| Total Cash | 2,201,000 |
| Total Cash Per Share | 0.412 |
| Total Debt | 355,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.16 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.116575 |
| Two Hundred Day Average Change | 0.073425055 |
| Two Hundred Day Average Change Percent | 0.023559533 |
| Type Disp | Equity |
| Volume | 12,477 |
| Website | https://newcelx.com |
| Zip | 8,302 |